A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Abstract
Annually in the US there are 2.8 million TBI-related ED visits, hospitalizations, and deaths and over 2 million individuals are diagnosed with mild TBI (mTBI). From 2000 to 2016, 360,000 US armed service members were diagnosed with TBIs, of which over 80 were mTBIs. Post-traumatic headache (PTH) is the most common symptom following mTBI. Although some PTHs resolve within the first few days, a large proportion of individuals with PTH do not have headache resolution during the acute phase and have PTH persistence (PPTH). Optimally, individuals who are at high risk for PPTH would be identified and treated during the acute stage of PTH, prior to and with the intent of preventing PTH persistence. This Focused Program will address this area of need by investigating mechanisms for PTH persistence, biomarkers that predict an increased risk for PPTH, and methods of preventing the development of PPTH. This Focused Program consists of six synergistic, non-interdependent, individual projects that address the overarching goal via use of PTH animal models, human investigations of individuals with PTH via in-depth phenotyping, neurophysiology testing, imaging brain structure and function, and via human and animal molecular and genetic biomarker identification. Finally, this Focused Program includes a phase II clinical trial of a CGRP receptor monoclonal antibody administered during the acute stage of PTH with the intent of preventing PTH persistence.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1155917
Entities
People
- Todd J. Schwedt
Organizations
- Mayo Clinic Hospital